SCHEMBL3079478

SCHEMBL3079478

OC1CNCCC1Oc1ccc(F)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 13/20 0.49
SLC6A4 P31645 11/20 0.49
SLC6A3 Q01959 8/20 0.49
CYP2D6 P10635 1/20 0.49
HTR2C P28335 3/20 0.43
HTR2B P41595 3/20 0.43
HRH1 P35367 1/20 0.41
HTR1A P08908 6/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAP2K1 Q02750 1/20 0.37
MPO P05164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17708362 0.84 HTR2C (0.43) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL18066866 0.81 CSNK2A1 (0.39) SLC6A2SLC6A4SLC6A3HTR2CHTR2B
SCHEMBL17708042 0.81 CYP2C19 (0.41) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL11236266 0.77 HTR2B (0.42) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL11236259 0.77 HTR2B (0.42) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL5369367 0.77 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL11244532 0.77 HTR2B (0.42) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL11236271 0.77 HTR2B (0.42) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
SCHEMBL11244526 0.77 HTR2B (0.42) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
Hydrochloric Acid SCHEMBL4106087 0.76 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079693-B1 ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HOFFMANN LA ROCHE (CH) 2013-02-27 EP disclosed
US-7795437-B2 Ether derivatives HOFFMANN-LA ROCHE INC. (US) 2010-09-14 US disclosed
EP-2079693-A1 ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS F. Hoffmann-Roche AG (CH) 2009-07-22 EP disclosed
WO-2008052899-A1 ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-08 WO disclosed
US-20080103174-A1 ETHER DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103174-A1 ETHER DERIVATIVES GABRE, BDNF, ADH1A SLC6A2 122/4885SLC6A4 366/4885SLC6A3 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.